



[Science Education Patient Care & Advocacy](#)
[Our Society](#) [Our Mission, Vision & Values](#) [EBMT Membership 2020](#) [Organisational Structure 2020](#) [Financial Highlights 2020](#) [EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Mohamad Mohty
ALWP Chair
France

Major achievements

This year has been incredibly difficult for everyone, and I am so grateful for your continuous support. COVID-19 may keep us in its grips for a little while longer, but the news of a vaccine, the introduction of more advanced testing, offer us hope of a return to a certain norm. Immediately after the start of the pandemic, the ALWP leadership and staff have worked hard to help our community during these hard

times. Thanks to a thorough evaluation, we were able to deliver some practical guidelines for the management of patients with acute leukemia during the COVID-19 outbreak. Also, we took immediate action to continue our studies and keep the members connected through different digital tools. Thanks to the booming use of haplo-identical donors, the number of HSCT procedures for patients with acute leukemia is continuously growing. This increase is accompanied by improving results, due to both lower risk of relapse (maintenance therapy post HSCT) and decreased non-relapse mortality. In 2020, and like in previous years, the ALWP published a high number of papers. We have also launched many new studies, especially a major initiative aiming to collect next-generation sequencing (NGS) data and use of novel drugs. Molecularly directed treatment options represent a significant advance in the field and they highlight the importance of NGS as a backbone of the clinical decision-making process, both at diagnosis and at time of relapse. Today, NGS allows for assessing the unique clonal hierarchy of an individual patient, leading to tailored treatment approaches, thereby providing improved outcomes. Identifying «druggable» mutations paves the way for the use of novel targeted therapies. This may represent an attractive bridging approach for reinduction before HSCT. Collecting such data will allow the generation of new knowledge to further advance the field. We would highly appreciate it if you could help by contributing to this important new study. All of these activities are possible thanks to all EBMT members who report their data voluntarily. Thank you again for your continued loyalty and this year, we honestly could not have done it without you. It is a true privilege and honor to lead the ALWP and serve EBMT.

Principal research studies

1. Analysis of the role of haploidentical donors in different disease settings
2. Prognostic impact of measurable residual disease (MRD) in the transplant setting for acute leukaemia
3. Role of the different agents to treat and prevent relapse post HSCT for acute leukaemia
4. Value of NGS data to predict transplant outcome
5. Building a consensus guideline for the analysis and use of MRD in leukaemia patients candidate to transplant

Key publications

2020

The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation

Group

Acute Leukemia Working Party (ALWP)

1st listed author

Xavier Poiré

Journal

Am J Hematol.

2020

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Group

Acute Leukemia Working Party (ALWP)

1st listed author

Bazarbachi AH

Journal

Biol Blood Marrow Transplant.

2020

Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.

Group

Acute Leukemia Working Party (ALWP)

1st listed author

Díaz-Beyá M

Journal

Br J Haematol.

2020

Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.

Group

Acute Leukemia Working Party (ALWP)

[1st listed author](#)

[El-Cheikh J](#)

[Journal](#)

[Clin Lymphoma Myeloma Leuk.](#)

[2020](#)

[Post-transplant Cyclophosphamide After Matched Sibling, Unrelated and Haploidentical Donor Transplants in Patients With Acute Myeloid Leukemia: A Comparative Study of the ALWP EBMT](#)

[Group](#)

[Acute Leukemia Working Party \(ALWP\)](#)

[1st listed author](#)

[Jaime Sanz](#)


[Journal](#)

[J Hematol Oncol.](#)

[See the full list of the ALWP 2020 publications](#)



Impact factor (Acute Leukemia)



	2015	2016	2017	2018	2019	2020
Oral presentations	22	30	39	28	24	17
Poster presentations	15	19	23	18	17	12
International educational events	3	2	2	3	1	2

Major educational courses

Two educational and business meetings [Virtual].